The Helmholtz Sino-German Research Laboratory for Cancer, Department of Pathology, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, Shaanxi, People's Republic of China.
Dig Dis Sci. 2011 Dec;56(12):3569-76. doi: 10.1007/s10620-011-1812-x. Epub 2011 Jul 26.
HAb18G/CD147 expression has been associated with many tumor invasion molecules, which play important roles in recurrence and poor differentiation of esophageal squamous cell carcinoma (ESCC). However, the clinical implications of HAb18G/CD147 in ESCC are still unclear.
In this study, we clarified the clinical significance of HAb18G/CD147 and characterized the association between HAb18G/CD147 and tumor invasion in ESCC cases.
Tumor tissues were obtained from 86 ESCC patients who underwent surgical resection between 2002 and 2005. All patients that had received previous therapy were excluded. ESCC tissues were analyzed by IHC using anti HAb18G/CD147 antibody. The expression of HAb18G/CD147 mRNA in esophageal cancer cell lines was analyzed by RT-PCR.
HAb18G/CD147 was uniformly expressed in EC109 and EC871214 cell lines, but negatively expressed in EPC2, esophageal normal squamous cell line. HAb18G/CD147 mainly localized to the membrane of tumor cells in 84.9% of ESCC patients (64 out of 86 cases). Furthermore, we also found that higher HAb18G/CD147 expression levels significantly correlated with lymph node metastasis, depth of tumor invasion and differentiation (P < 0.05). But the expression levels of HAb18G/CD147 in lymph node metastatic tissues were almost equal to that in the primary tumor tissues. Furthermore, lymph node metastasis and expression of HAB18G/CD147 were independent prognostic indicators in ESCC.
The expression of HAb18G/CD147 might be involved in the progression and survival of ESCC. Therefore, HAb18G/CD147 could be a clinical marker for the poor prognosis in ESCC patients and may also be a potentially therapeutic target to improve the progression of ESCC.
HAb18G/CD147 的表达与许多肿瘤侵袭分子相关，这些分子在食管鳞状细胞癌（ESCC）的复发和分化不良中发挥重要作用。然而，HAb18G/CD147 在 ESCC 中的临床意义尚不清楚。
本研究旨在阐明 HAb18G/CD147 的临床意义，并描述其与 ESCC 肿瘤侵袭之间的关联。
收集 2002 年至 2005 年间接受手术切除的 86 例 ESCC 患者的肿瘤组织。所有接受过先前治疗的患者均被排除在外。使用抗 HAb18G/CD147 抗体通过免疫组织化学法分析 ESCC 组织。通过 RT-PCR 分析食管癌细胞系中 HAb18G/CD147 mRNA 的表达。
HAb18G/CD147 在 EC109 和 EC871214 细胞系中均匀表达，但在 EPC2（食管正常鳞状细胞系）中阴性表达。在 84.9%（64/86 例）的 ESCC 患者中，HAb18G/CD147 主要定位于肿瘤细胞的膜上。此外，我们还发现 HAb18G/CD147 表达水平越高，与淋巴结转移、肿瘤浸润深度和分化程度显著相关（P<0.05）。但是，淋巴结转移组织中 HAb18G/CD147 的表达水平几乎与原发肿瘤组织中的表达水平相等。此外，淋巴结转移和 HAB18G/CD147 的表达是 ESCC 的独立预后指标。
HAb18G/CD147 的表达可能参与 ESCC 的进展和生存。因此，HAb18G/CD147 可能是 ESCC 患者预后不良的临床标志物，也可能是改善 ESCC 进展的潜在治疗靶点。
